1
|
Papiris SA, Louvrier C, Fabre A, Kaklamanis L, Tsangaris I, Frantzeskaki F, Dimeas IE, Debray MP, Karakontaki F, Kallieri M, Kolilekas L, Daniil Z, Giatromanolaki A, Kannengiesser C, Borie R, Nathan N, Griese M, Manali ED. CSF2RB mutation-related hereditary pulmonary alveolar proteinosis: the "long and winding road" into adulthood. ERJ Open Res 2023; 9:00703-2023. [PMID: 38111540 PMCID: PMC10726220 DOI: 10.1183/23120541.00703-2023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2023] [Accepted: 10/03/2023] [Indexed: 12/20/2023] Open
Abstract
Genetic analysis pre-lung transplantation diagnosed a case of hereditary pulmonary alveolar proteinosis (PAP) complicated by fibrosis in adulthood. The need for genetic testing in GM-CSF autoantibody negative and unclassifiable PAP is highlighted. https://bit.ly/3QcsYwM.
Collapse
Affiliation(s)
- Spyros A. Papiris
- 2nd Pulmonary Department, General University Hospital “Attikon”, Medical School, National and Kapodistrian University of Athens, Athens, Greece
- These authors contributed equally to this work
| | - Camille Louvrier
- Sorbonne Université, Inserm, Laboratory of Childhood Genetic Disorders, UMR S933, Hôpital Armand-Trousseau, Paris, France
- Département de Génétique Médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Armand-Trousseau, Paris, France
- These authors contributed equally to this work
| | - Aurélie Fabre
- Department of Pathology, St Vincent's University Hospital, Dublin, Ireland
- School of Medicine, University College Dublin, Dublin, Ireland
| | - Loukas Kaklamanis
- Heart Failure and Transplant Units, Onassis Cardiac Surgery Center, Athens, Greece
| | - Iraklis Tsangaris
- 2nd Department of Critical Care Medicine, General University Hospital “Attikon”, Medical School, National and Kapodistrian University of Athens, Athens, Greece
| | - Frantzeska Frantzeskaki
- 2nd Department of Critical Care Medicine, General University Hospital “Attikon”, Medical School, National and Kapodistrian University of Athens, Athens, Greece
| | - Ilias E. Dimeas
- Department of Respiratory Medicine, Faculty of Medicine, University of Thessaly, Biopolis, Larissa, Greece
| | - Marie-Pierre Debray
- Service de Radiologie, Hôpital Bichat, APHP, Paris, France
- INSERM, Unité 1152, Université de Paris, Paris, France
| | - Foteini Karakontaki
- 1st Respiratory Medicine Department, National and Kapodistrian University of Athens, Medical School, “Sotiria” Chest Hospital, Athens, Greece
| | - Maria Kallieri
- 2nd Pulmonary Department, General University Hospital “Attikon”, Medical School, National and Kapodistrian University of Athens, Athens, Greece
| | | | - Zoe Daniil
- Department of Respiratory Medicine, Faculty of Medicine, University of Thessaly, Biopolis, Larissa, Greece
| | - Alexandra Giatromanolaki
- Department of Pathology, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece
| | - Caroline Kannengiesser
- Département de Génétique, APHP Hôpital Bichat, Université de Paris, Paris, France
- INSERM UMR 1152, Université de Paris, Paris, France
| | - Raphael Borie
- Service de Pneumologie A, INSERM UMR_1152, Centre de Référence des Maladies Pulmonaires Rares, FHU APOLLO, APHP Hôpital Bichat, Sorbonne Université, Paris, France
| | - Nadia Nathan
- Pediatric Pulmonology Department and Reference Centre for Rare Lung Diseases RespiRare, INSERM UMR_S933 Laboratory of Childhood Genetic Diseases, Armand Trousseau Hospital, Sorbonne University and APHP, Paris, France
| | - Matthias Griese
- Department of Pediatric Pneumology, Dr von Hauner Children's Hospital, Ludwig-Maximilians-University, German Center for Lung Research, Munich, Germany
| | - Effrosyni D. Manali
- 2nd Pulmonary Department, General University Hospital “Attikon”, Medical School, National and Kapodistrian University of Athens, Athens, Greece
| |
Collapse
|
2
|
Steiropoulos P, Exarchos K, Bertoli M, Karakontaki F, Antonogiannakis G, Polychronopoulos V, Gogali A, Kostikas K. Effectiveness and Quality of life in asthmatic patients treated with budesonide/formoterol via Elpenhaler® device in primary care. The "SKIRON" real world study. J Asthma 2022; 60:1104-1114. [PMID: 36199217 DOI: 10.1080/02770903.2022.2132957] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Aim Inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) combination therapy is used for the effective control of asthma. Aim of this study was to collect data on the effectiveness, safety, quality of life, and patient satisfaction from a fixed dose combination of budesonide/formoterol administered with the Elpenhaler® device following 3-months' treatment.Methods A 3-month real-life, multicentre, one-arm, prospective observational study (SKIRON study-NCT03055793) was conducted, using the following questionnaires: Asthma Control Questionnaire (ACQ-6) for asthma control assessment, MiniAQLQ questionnaire for QoL assessment, and Feeling of Satisfaction with Inhaler questionnaire (FSI-10) for patients' satisfaction with the inhaler device. Comorbidities and safety data were also recorded during the study.Results We enrolled 1,174 asthmatic patients following standard clinical practice in primary care from 126 sites in urban and rural areas of Greece. The majority of patients (71.5%) had at least one comorbidity. A statistically significant improvement in the ACQ-6 score was noted at 3 months compared to the baseline evaluation (mean ± SD 2.19 ± 0.97 at baseline vs. 0.55 ± 0.56 at 3 months; mean change -1.64 (95%CI -1.69, -1.57), p < 0.0001). MiniAQLQ score was statistically and clinically significantly improved, compared to baseline, (4.55 ± 1.04 at baseline vs. 6.37 ± 0.64 at 3 months; mean change 1.82 (95%CI 1.75, 1.87), p < 0.0001). The mean FSI-10 score of 44.2 ± 5.4 indicated patient satisfaction and ease-of-use of the Elpenhaler® device.Conclusions In this large real-world study of inadequately-controlled asthma patients in primary care settings, the treatment with budesonide/formoterol FDC with the Elpenhaler® device was associated with significant improvement in patients' asthma control and quality of life.
Collapse
Affiliation(s)
- Paschalis Steiropoulos
- University General Hospital of Alexandroupolis, Department of Pulmonology, Dragana 68100, Alexandroupolis, Greece
| | | | - Maria Bertoli
- Medical Department, ELPEN Pharmaceutical Co. Inc., 95, Marathonos Av., 19009, Pikermi, Attica
| | - Foteini Karakontaki
- Pulmonary Clinic, Hygeia Hospital, 4, Erythrou Stavrou Str. & Kifisias Av., 15123 Marousi, Athens
| | | | | | - Athena Gogali
- University of Ioannina School of Medicine, Ioannina, Greece
| | | |
Collapse
|
3
|
Kampolis CF, Venetsanopoulou AI, Karakontaki F, Polychronopoulos V, Vlachoyiannopoulos P, Tzioufas AG. How can autoantibodies predict the long-term outcome of patients with interstitial lung disease? Results from a retrospective cohort study. Autoimmun Rev 2018; 17:1124-1133. [DOI: 10.1016/j.autrev.2018.06.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2018] [Accepted: 06/19/2018] [Indexed: 01/07/2023]
|
4
|
Papaioannou AI, Bartziokas K, Loukides S, Tsikrika S, Karakontaki F, Haniotou A, Papiris S, Stolz D, Kostikas K. Cardiovascular comorbidities in hospitalised COPD patients: a determinant of future risk? Eur Respir J 2015; 46:846-9. [PMID: 25882807 DOI: 10.1183/09031936.00237014] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2014] [Accepted: 03/18/2015] [Indexed: 11/05/2022]
Affiliation(s)
| | | | - Stelios Loukides
- 2nd Respiratory Medicine Dept, University of Athens Medical School, Athens, Greece
| | - Stamatoula Tsikrika
- 3rd Respiratory Medicine Dept, Sismanogleion General Hospital, Athens, Greece
| | - Foteini Karakontaki
- 3rd Respiratory Medicine Dept, Sismanogleion General Hospital, Athens, Greece
| | | | - Spyros Papiris
- 2nd Respiratory Medicine Dept, University of Athens Medical School, Athens, Greece
| | - Daiana Stolz
- Respiratory Medicine Dept, University Hospital, Basel, Switzerland
| | | |
Collapse
|
5
|
Diamantea F, Kostikas K, Bartziokas K, Karakontaki F, Tsikrika S, Pouriki S, Polychronopoulos V, Karagiannidis N, Haniotou A, Papaioannou AI. Prediction of Hospitalization Stay in COPD Exacerbations: The AECOPD-F Score. Respir Care 2014; 59:1679-86. [DOI: 10.4187/respcare.03171] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
6
|
Karakontaki F, Gennimata SA, Palamidas AF, Anagnostakos T, Kosmas EN, Stalikas A, Papageorgiou C, Koulouris NG. Driving-Related Neuropsychological Performance in Stable COPD Patients. Pulm Med 2013; 2013:297371. [PMID: 23431438 PMCID: PMC3575615 DOI: 10.1155/2013/297371] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2012] [Accepted: 12/24/2012] [Indexed: 11/17/2022] Open
Abstract
Background. Cognitive deterioration may impair COPD patient's ability to perform tasks like driving vehicles. We investigated: (a) whether subclinical neuropsychological deficits occur in stable COPD patients with mild hypoxemia (PaO(2) > 55 mmHg), and (b) whether these deficits affect their driving performance. Methods. We recruited 35 stable COPD patients and 10 normal subjects matched for age, IQ, and level of education. All subjects underwent an attention/alertness battery of tests for assessing driving performance based on the Vienna Test System. Pulmonary function tests, arterial blood gases, and dyspnea severity were also recorded. Results. COPD patients performed significantly worse than normal subjects on tests suitable for evaluating driving ability. Therefore, many (22/35) COPD patients were classified as having inadequate driving ability (failure at least in one of the tests), whereas most (8/10) healthy individuals were classified as safe drivers (P = 0.029). PaO(2) and FEV1 were correlated with almost all neuropsychological tests. Conclusions. COPD patients should be warned of the potential danger and risk they face when they drive any kind of vehicle, even when they do not exhibit overt symptoms related to driving inability. This is due to the fact that stable COPD patients may manifest impaired information processing operations.
Collapse
Affiliation(s)
- Foteini Karakontaki
- Respiratory Function Laboratory, 1st Department of Respiratory Medicine, National University of Athens, “Sotiria” Hospital, 152 Mesogeion Ave, 11527 Athens, Greece
| | - Sofia-Antiopi Gennimata
- Respiratory Function Laboratory, 1st Department of Respiratory Medicine, National University of Athens, “Sotiria” Hospital, 152 Mesogeion Ave, 11527 Athens, Greece
| | - Anastasios F. Palamidas
- Respiratory Function Laboratory, 1st Department of Respiratory Medicine, National University of Athens, “Sotiria” Hospital, 152 Mesogeion Ave, 11527 Athens, Greece
| | - Theocharis Anagnostakos
- Respiratory Function Laboratory, 1st Department of Respiratory Medicine, National University of Athens, “Sotiria” Hospital, 152 Mesogeion Ave, 11527 Athens, Greece
| | - Epaminondas N. Kosmas
- Respiratory Function Laboratory, 1st Department of Respiratory Medicine, National University of Athens, “Sotiria” Hospital, 152 Mesogeion Ave, 11527 Athens, Greece
| | - Anastasios Stalikas
- Hellenic Sports Research Institute, Olympic Sports Centre of Athens, 37 Kifisias Ave, Marousi, 15123 Athens, Greece
| | - Charalambos Papageorgiou
- Respiratory Function Laboratory, 1st Department of Respiratory Medicine, National University of Athens, “Sotiria” Hospital, 152 Mesogeion Ave, 11527 Athens, Greece
| | - Nikolaos G. Koulouris
- Respiratory Function Laboratory, 1st Department of Respiratory Medicine, National University of Athens, “Sotiria” Hospital, 152 Mesogeion Ave, 11527 Athens, Greece
| |
Collapse
|
7
|
Papaioannou AI, Bartziokas K, Tsikrika S, Karakontaki F, Kastanakis E, Banya W, Haniotou A, Papiris S, Loukides S, Polychronopoulos V, Kostikas K. The impact of depressive symptoms on recovery and outcome of hospitalised COPD exacerbations. Eur Respir J 2012; 41:815-23. [PMID: 22878874 DOI: 10.1183/09031936.00013112] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The impact of depressive symptoms on outcomes of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) has not been thoroughly evaluated in prospective studies. We prospectively enrolled 230 consecutive patients hospitalised for AECOPD, without previous diagnosis of depression. Depressive symptoms were evaluated with Beck's depression inventory. Pulmonary function tests, arterial blood gases, COPD assessment test (CAT) and Borg dyspnoea scale were recorded on admission and on days 3, 10 and 40. Patients were evaluated monthly for 1 year. Patients with depressive symptoms required longer hospitalisation (mean ± sd 11.6 ± 3.7 versus 5.6 ± 4.1 days, p<0.001). Clinical variables improved during the course of AECOPD, but depressive symptoms on admission had a significant impact on dyspnoea (p<0.001) and CAT score (p = 0.012) improvement. Patients with depressive symptoms presented more AECOPD (p<0.001) and more hospitalisations for AECOPD (p<0.001) in 1 year. In multivariate analysis, depressive symptoms were an independent predictor of mortality (hazard ratio 3.568, 95% CI 1.302-9.780) and risk for AECOPD (incidence rate ratio (IRR) 2.221, 95% CI 1.573-3.135) and AECOPD hospitalisations (IRR 3.589, 95% CI 2.319-5.556) in 1 year. The presence of depressive symptoms in patients admitted for AECOPD has a significant impact on recovery and is related to worse survival and increased risk for subsequent COPD exacerbations and hospitalisations in 1 year.
Collapse
|